Mon . 19 Apr 2019

Telithromycin

telithromycin, telithromycin brand name
Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek It is used to treat community acquired pneumonia of mild to moderate severity After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007

Telithromycin is a semi-synthetic erythromycin derivative It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring An alkyl-aryl moiety is attached to this carbamate ring Furthermore, the carbon at position 6 has been methylated, as is the case in clarithromycin, to achieve better acid-stability

Contents

  • 1 History
    • 11 Development and approval
    • 12 Safety controversies and fraud
    • 13 FDA Warning
  • 2 Available forms
  • 3 Mechanism of action
  • 4 Pharmacokinetics
  • 5 Metabolism
  • 6 Adverse effects
  • 7 References
  • 8 External links

History

Development and approval

French pharmaceutical company Hoechst Marion Roussel later Sanofi-Aventis began phase II/III clinical trials of telithromycin HMR-3647 in 1998 Telithromycin was approved by the European Commission in July 2001 and subsequently went on sale in October 2001 In the US, telithromycin received US Food and Drug Administration FDA approval on April 1, 2004

Safety controversies and fraud

FDA staffers publicly complained that safety problems and some data integrity issues were ignored prior to approval, and the House Committee on Energy and Commerce held hearings to examine these complaints One doctor went to prison because she falsified data in her portion of the clinical trials about 400 patients out of 24,000 Further, Ketek seemed to cause liver problems, including "liver failure", to a greater extent than would be expected of a common-use antibiotic The House Committee on Energy and Commerce held hearings

Study 3014 was a key clinical trial of approximately 24,000 patients which Sanofi-Aventis submitted to the FDA to seek approval for Ketek The doctor who treated the most patients in Study 3014 about 400, Maria "Anne" Kirkman Campbell, served a 57-month sentence in federal prison after pleading guilty to mail fraud, by defrauding Aventis and others The indictment states that Campbell fabricated data she sent to the company Documents, including internal Sanofi-Aventis emails show that Aventis was worried about Campbell early in study 3014 but didn't tell the FDA until the agency's own inspectors discovered the problem independently

In January 2006, an article in the March issue of Annals of Internal Medicine was published, citing three recent drug-induced liver injury cases likely due to telithromycin, one resulting in a liver transplant and one in death

In July 2006, according to the New York Times, unpublished e-mails from FDA safety official David Graham argued telithromycin had not been proven safe, that safer drugs were available for the same indications, and that the approval was a mistake and should be immediately withdrawn

Between the start of telithromycin's marketing in mid-2004 and September 2006, there were 13 cases of liver failure, including at least four deaths, vision problems, blackouts, syncope, and potentially fatal cases of myasthenia gravis The Times said that the FDA was embroiled in a "fierce battle" over the approval, fueled by exposure in the press Senator Charles E Grassley R-Iowa, chairman, Senate Finance Committee, Representatives Edward J Markey D-Mass and Henry A Waxman D-Calif held hearings

FDA Warning

On February 12, 2007, after an advisory committee discussion and vote in December 2006, the FDA announced a revision to the labeling of Ketek The changes included the removal of two of the three previously approved indications: acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis The agency determined that the balance of benefits and risks no longer supported approval of the drug for these indications Ketek remained on the market for the treatment of community acquired bacterial pneumonia of mild to moderate severity acquired outside of hospitals or long-term care facilities In addition, the FDA worked with the manufacturer to update the product labeling with a "black box warning," their strongest form of warning Ketek's warning states that it should not be used in patients with myasthenia gravis, a disease that causes muscle weakness Following this decision, Sanofi-Aventis withdrew the drug from active sales in the United States

Available forms

Telithromycin is administered as tablets The standard dosing is two 400 mg tablets to be taken together daily, with or without food

Mechanism of action

Telithromycin prevents bacteria from growing, by interfering with their protein synthesis Telithromycin binds to the subunit 50S of the bacterial ribosome, and blocks the progression of the growing polypeptide chain Telithromycin has over 10 times higher affinity to the subunit 50S than erythromycin In addition, telithromycin strongly bind simultaneously to two domains of 23S RNA of the 50 S ribosomal subunit, where older macrolides bind strongly only to one domain and weakly to the second domain Like many other protein synthesis inhibitors, telithromycin can also inhibit the formation of ribosomal subunits 50S and 30S

Pharmacokinetics

Unlike erythromycin, telithromycin is acid-stable and can therefore be taken orally while being protected from gastric acids It is fairly rapidly absorbed, and diffused into most tissues and phagocytes Due to the high concentration in phagocytes, telithromycin is actively transported to the site of infection During active phagocytosis, large concentrations of telithromycin is released The concentration of telithromycin in the tissues is much higher than in plasmaTelithromycin fulfills a role that has arisen due to the rise of microbial resistance to existing macrolides and appears to be effective against macrolide-resistant Streptococcus pneumoniae The defining differentiating characteristic of the ketolides as opposed to other macrolides is the removal of the neutral sugar, L-cladinose from the 3 position of the macrolide ring and the subsequent oxidation of the 3-hydroxyl to a 3-keto functional group

Metabolism

Telithromycin is metabolized mainly in the liver, the main elimination route being the bile, a small portion is also excreted into the urine About one third is excreted unchanged in bile and urine, the biliary route being favoured Telithromycin's half-life is approximately ten hours

Adverse effects

Most common side-effects are gastrointestinal, including diarrhea, nausea, abdominal pain and vomiting Headache and disturbances in taste also occur Less common side-effects include palpitations, blurred vision, and rashes Prolonged QTc intervals may also be caused by telithromycin

Rare but severe side-effects were initially reported in March 2006, involving damage to the liver Three different incidents were reported: one case of temporary drug-induced hepatitis, one ending in a liver transplant, and one ending in death

In the United States, the FDA's Office of Epidemiology and Surveillance identified 12 cases of acute liver failure, resulting in four deaths, and an additional 23 cases of acute, serious liver injury, among 52 million patients taking telithromycin through April 2006

In 2010, a published report described the likely mechanism of action underlying not only the cases of liver failure but also cases of visual disturbances and exacerbations of myasthenia gravis The study showed that a pyridine moiety that is part of the telithromycin molecule acts as an antagonist on cholinergic receptors located in the neuromuscular junction, the ciliary ganglion of the eye and the vagus nerve innervating the liver Other macrolides, such as azithromycin and clarithromycin and the fluoroketolide, solithromycin, do not contain the pyridine moiety and do not antagonize these cholinergic receptors significantly

References

  1. ^ Splete, Heidi; Kerri Wachter March 2006 "Liver toxicity reported with Ketek" Internal Medicine News 
  2. ^ House of Representatives, The House Committee on Energy and Commerce, Honorable John D Dingell, Chairman, Subcommittee on Oversight and Investigations, "The Adequacy of FDA Efforts to Assure the Safety of the Drug Supply", February 13, 2007
  3. ^ Food and Drug Administration, NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN NIDPOE, Leslie Ball, 5/18/2006
  4. ^ Infected Data: Fraud, Errors Taint Key Study Of Widely Used Sanofi Drug Despite Some Faked Results, FDA Approves Antibiotic; One Doctor's Cocaine Use; Company Defends Safety, By ANNA WILDE MATHEWS, Wall Street Journal, May 1, 2006
  5. ^ a b Clay KD, et al 2006 "Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review" Annals of Internal Medicine 144 6: 415–420 doi:107326/0003-4819-144-6-200503210-00121 PMID 16481451 
  6. ^ Gardiner Harris 2006-07-19 "Approval of Antibiotic Worried Safety Officials" New York Times Retrieved 2010-05-25 
  7. ^ http://wwwfdagov/bbs/topics/NEWS/2007/NEW01561html
  8. ^ Eyal, Z; Matzov, D; Krupkin, M; Wekselman I; Paukner S; Zimmerman, E; Rozenberg, H; Bashan, A; Yonath, A 2015 "Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus" Proc Natl Acad Sci U S A 112 43: E5805–14 doi:101073/pnas1517952112 PMC 4629319  PMID 26464510 
  9. ^ Scheinfeld N Telithromycin: A brief review of a new ketolide antibiotic J Drug Dermat 2004;3:409-13 PMID 15303785
  10. ^ Bertram G Katzung, Susan B Masters, Anthony J Trevor Basic & Clinical Pharmacology, 11e McGraw-Hill 2009 via "accessmedicinecom"
  11. ^ http://wwwfdagov/ohrms/dockets/AC/06/slides/2006-4266s1-01-07-FDA-Brinkerppt
  12. ^ "Fraud, Errors Taint Key Study Of Widely Used Sanofi Drug - WSJ" 
  13. ^ Bertrand, D; Bertrand, S; Neveu, E; Fernandes, P 2010 "Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors" Antimicrobial Agents and Chemotherapy 54: 5399–5402 doi:101128/aac00840-10 

External links

  • FDA Public Health Advisory for Telithromycin marketed as Ketek
  • Article in Annals of Internal Medicine regarding cases of hepatotoxicity induced by telithromycin
  • New York Times article Login is required
  • FDA officials question safety of antibiotic 'Ketek'
  • Drugs and Treatments - KETEK Oral - Patient Handout from WebMD

telithromycin, telithromycin (ketek), telithromycin and myasthenia gravis, telithromycin antibiotic, telithromycin brand name, telithromycin classification, telithromycin contraindications, telithromycin prescribing information, telithromycin side effects, telithromycin structure


Telithromycin Information about

Telithromycin


  • user icon

    Telithromycin beatiful post thanks!

    29.10.2014


Telithromycin
Telithromycin
Telithromycin viewing the topic.
Telithromycin what, Telithromycin who, Telithromycin explanation

There are excerpts from wikipedia on this article and video

Random Posts

Timeline beyond October following the September 11 attacks

Timeline beyond October following the September 11 attacks

The following list contains certain dates beyond October 2001 involving the September 11 attacks ...
Smash Hits

Smash Hits

Smash Hits was a pop music magazine, aimed at teenagers and young adults and originally published in...
2014–15 USC Trojans women's basketball team

2014–15 USC Trojans women's basketball team

The 2014–15 USC Trojans women's basketball team will represent University of Southern California dur...
Trademark classification

Trademark classification

A trademark classification is a way the trademark examiners and applicants' trademark attorneys arra...